Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:CASNumber |
923032-37-5
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Bayer
gptkb:Ardea_Biosciences |
| gptkbp:hasInChIKey |
QJQYQKZQJYJZQJ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C17H14F3IN2O2
|
| gptkbp:hasSMILES |
COC1=CC2=C(C=C1)N=C(NC2=O)C3=CC=C(C=C3)C(F)(F)F
|
| gptkbp:hasUNII |
6QX8J8QK1U
|
| https://www.w3.org/2000/01/rdf-schema#label |
refametinib
|
| gptkbp:indication |
gptkb:cancer
solid tumors hepatocellular carcinoma |
| gptkbp:mechanismOfAction |
MEK inhibitor
|
| gptkbp:molecularWeight |
478.2 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
25154816 DB11760 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:BAY_86-9766
gptkb:RDEA119 |
| gptkbp:target |
gptkb:MEK1
gptkb:MEK2 |
| gptkbp:bfsParent |
gptkb:MEK_inhibitors
|
| gptkbp:bfsLayer |
6
|